CN112996498B - 在预防或治疗运动员过度训练中使用的化合物 - Google Patents

在预防或治疗运动员过度训练中使用的化合物 Download PDF

Info

Publication number
CN112996498B
CN112996498B CN201980065370.4A CN201980065370A CN112996498B CN 112996498 B CN112996498 B CN 112996498B CN 201980065370 A CN201980065370 A CN 201980065370A CN 112996498 B CN112996498 B CN 112996498B
Authority
CN
China
Prior art keywords
subject
overtraining
training
hydroxybutyric acid
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980065370.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112996498A (zh
Inventor
K·克拉克
P·亨斯佩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tederta Co ltd
Original Assignee
Tederta Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tederta Co ltd filed Critical Tederta Co ltd
Publication of CN112996498A publication Critical patent/CN112996498A/zh
Application granted granted Critical
Publication of CN112996498B publication Critical patent/CN112996498B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980065370.4A 2018-10-04 2019-10-03 在预防或治疗运动员过度训练中使用的化合物 Active CN112996498B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816196.8A GB2577723A (en) 2018-10-04 2018-10-04 Compounds for new use
GB1816196.8 2018-10-04
PCT/GB2019/052797 WO2020070506A1 (en) 2018-10-04 2019-10-03 Compounds for use in preventing or treating athlete overtraining

Publications (2)

Publication Number Publication Date
CN112996498A CN112996498A (zh) 2021-06-18
CN112996498B true CN112996498B (zh) 2024-10-29

Family

ID=68242730

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980065370.4A Active CN112996498B (zh) 2018-10-04 2019-10-03 在预防或治疗运动员过度训练中使用的化合物

Country Status (9)

Country Link
US (1) US12290496B2 (https=)
EP (1) EP3860584B1 (https=)
JP (1) JP7575163B2 (https=)
KR (1) KR102868881B1 (https=)
CN (1) CN112996498B (https=)
AU (1) AU2019351925B2 (https=)
CA (1) CA3114889A1 (https=)
GB (2) GB2577723A (https=)
WO (1) WO2020070506A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100020441A1 (it) 2021-07-30 2023-01-30 Unichem Estense S R L Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici
CN118591523A (zh) * 2021-11-12 2024-09-03 阿萨达股份公司 多元醇衍生的化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6323237B1 (en) 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
EP1648952B1 (en) * 2003-06-03 2018-03-07 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
SE0400355D0 (sv) 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
WO2006020137A2 (en) 2004-07-16 2006-02-23 Ketocytonyx Inc. Oligomeric compounds
EP1778615A4 (en) 2004-07-20 2010-01-06 Btg Int Ltd OLIGOMERE KETONE COMPOUNDS
CN100344280C (zh) * 2005-08-01 2007-10-24 清华大学 3－羟基丁酸及其衍生物的新用途
WO2008110034A1 (en) 2007-03-14 2008-09-18 Shantou University 3-hydroxy fatty acid and its derivatives for improving of learning and/or memory of subjects
EP2240017B1 (en) 2008-01-04 2019-03-13 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
JP5773870B2 (ja) 2008-08-21 2015-09-02 アイシス イノヴェイション リミテッド ヒドロキシ酪酸エステル及びその医学的使用
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
GB201206192D0 (en) * 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
GB2515603B (en) 2013-03-14 2015-10-14 Isis Innovation Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate
CA2902603C (en) 2013-03-19 2021-03-02 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
US20150283163A1 (en) * 2014-04-04 2015-10-08 Organic Medical Ventures, L.L.C. Muscle treatment composition and method making same
US20180008629A1 (en) 2015-01-29 2018-01-11 Yale University Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CA3021784A1 (en) 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
GB201710229D0 (en) 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes;Pete J. Cox;《Cell Metabolism》;第24卷;256–268 *

Also Published As

Publication number Publication date
CA3114889A1 (en) 2020-04-09
JP2022504207A (ja) 2022-01-13
KR20210079304A (ko) 2021-06-29
WO2020070506A1 (en) 2020-04-09
KR102868881B1 (ko) 2025-10-15
GB2592803B (en) 2022-11-09
GB2592803A (en) 2021-09-08
US20210338612A1 (en) 2021-11-04
EP3860584A1 (en) 2021-08-11
JP7575163B2 (ja) 2024-10-29
AU2019351925A1 (en) 2021-04-15
GB202105967D0 (en) 2021-06-09
CN112996498A (zh) 2021-06-18
AU2019351925B2 (en) 2024-12-05
EP3860584B1 (en) 2026-02-18
GB2577723A (en) 2020-04-08
US12290496B2 (en) 2025-05-06

Similar Documents

Publication Publication Date Title
JP7632979B2 (ja) 肝臓脂肪を減らすことにおいて使用するための３－ヒドロキシ酪酸化合物
EP2833882B1 (en) Ketone bodies and ketone body esters for maintaining or improving muscle power output
JP6830359B2 (ja) 栄養組成物
ES2885678T3 (es) Cuerpo cetónico y éster de cuerpo cetónico para reducir la degradación muscular
ES2655367T3 (es) Bebida que comprende éster de hidroxibutirato y uso médico de la misma
WO2020054795A1 (ja) 老化防止剤及び老化防止方法
US20100280123A1 (en) Food supplement containing alpha-keto acids for supporting diabetes therapy
AU2018343110B2 (en) Hunger Suppression
KR101734152B1 (ko) 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
JP2024513567A (ja) １－メチルキサンチンをベースにした生物活性組成物およびそれを使用する方法
CN112996498B (zh) 在预防或治疗运动员过度训练中使用的化合物
CA2985564C (en) Compositions comprising cinnamaldehyde and zinc and methods of using such compositions
CN112384211A (zh) 用于癌症恶病质的化合物
CN117979971A (zh) 基于1-甲基黄嘌呤的生物活性组合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant